Table 2.
Clinical response to ACTH gel in terms of ocular inflammation.
| Patient No. | Ocular Findings at Start of ACTH Gel Treatment |
Ocular Findings at Last Follow-Up on ACTH Gel Treatment |
Concomitant Medications at Last Follow-Up | Treatment Duration (months) | ||||
|---|---|---|---|---|---|---|---|---|
| BCVA (OD/OS) | Anterior Segment Inflammation (0–4+) |
Posterior Segment Inflammation (0–4+) |
BCVA (OD/OS) | Anterior Segment Inflammation (0–4+) | Posterior Segment Inflammation (0–4+) | |||
| 1 | 20/70; 20/40 | +0.5 OU | +0.5 OU | 20/30; 20/40 | 0 OU | 0 OU | prednisone 5 mg/day |
15 |
| 2 | 20/400; 20/200 | +2 OD; +1 OS |
+1 OD | 20/150; 20/60 | 0 OU | 0 OU | none | 14 |
| 3 | 20/50; 20/80 | +2 OS | +0.5 OS | 20/40; 20/60 | 0 OU | 0 OU | prednisone 3 mg/day, MTX 7.5 mg/week |
12 |
BCVA, best corrected visual acuity; OD, right eye; OS, left eye; OU, both eyes; mg, milligram; MTX, methotrexate.